University of Kansas Alzheimer's Disease Research Center (KU ADRC)

堪萨斯大学阿尔茨海默病研究中心 (KU ADRC)

• 批准号: 10264622
• 负责人: RUSSELL H. SWERDLOW
• 金额: $ 303.84万
• 依托单位: UNIVERSITY OF KANSAS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-15 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10264622
• 关键词: Address; Affect; Alzheimer disease prevention; Alzheimer' s Disease; Alzheimer' s disease brain; Alzheimer' s disease care; Alzheimer' s disease pathology; Alzheimer' s disease patient; Alzheimer' s disease risk; Area; Automobile Driving; Back; Bioenergetics; Biological Markers; Brain; Caring; Cells; Center Core Grants; Clinic; Clinical; Clinical Trials; Collaborations; Development; Disease; Education; Energy Metabolism; Functional disorder; Funding; Gap Junctions; Genes; Genetic; Goals; Grant; Infrastructure; International; Intervention; Intervention Studies; Kansas; Knowledge; Life Style; Life Style Modification; Link; Metabolism; Mitochondria; Mitochondrial Diseases; Persons; Pharmacology; Play; Prevention; Prevention Research; Process; Proteins; Publications; Research; Research Personnel; Research Project Grants; Resources; Role; Science; Symptoms; Testing; Therapeutic; Therapeutic Intervention; Universities; Work; aging brain; bench to bedside; clinical care; clinical implementation; clinical practice; health care delivery; implementation science; innovation; lifestyle intervention; metabolic abnormality assessment; novel; programs; protein aggregation; proteostasis; ranpirnase; success; targeted treatment

ABSTRACT: OVERALL The University of Kansas Alzheimer's Disease Research Center (KU ADRC) promotes Alzheimer's Disease and Related Disorders (ADRD) research at local, national, and international levels. Our strengths in basic and translational mitochondria, lifestyle modification, and prevention research define a metabolism theme we pursued and refined over the past decade. We boast a sophisticated and mature infrastructure that advances a better understanding of AD, better care of affected persons, and new treatment interventions. The KU ADRC will use its intellectual and infrastructure assets this next cycle to drive AD research at a university vested and investing in our success, and in doing so move the field closer to a cure. Our Center moves seamlessly between bench and bedside, both in terms of the research projects we support, and in the infrastructure required to back investigator projects. Lifestyle intervention research generates fundamental mechanistic questions we call on wet lab investigators to address, and questions of clinical implementation and practice are now the focus of dry lab, clinical, and health care delivery investigators. Research addressing AD's mitochondrial component demonstrate a role for mitochondrial genes in AD risk, that mitochondria play a critical role in cell proteostasis and protein aggregation, specific links between mitochondria and AD hallmark proteins, and how to manipulate brain energy metabolism through lifestyle and pharmacologic approaches. To date these efforts led us to create novel compounds that constitute a unique therapeutic pipeline, and clinical trial infrastructure that supports actual studies of metabolism interventions in actual AD patients. For the 2021-26 cycle we will use our intellectual and infrastructure assets to address critical gaps in the AD field, including gaps in fundamental knowledge and care implementation. During this cycle the KU ADRC will work to (1) Empower innovative AD and brain aging research, education, and clinical programs; (2) Drive field-defining metabolism research, and (3) Bring practical and novel metabolism-directed therapies to the bedside and clinic.

摘要：总体 堪萨斯大学阿尔茨海默病研究中心 (KU ADRC) 促进阿尔茨海默病 地方、国家和国际层面的疾病及相关病症 (ADRD) 研究。我们的优势在于 基础和转化线粒体、生活方式改变和预防研究定义了新陈代谢主题 十年来我们不断追求、不断完善。我们拥有先进且成熟的基础设施， 促进人们更好地了解 AD、更好地护理受影响的人以及新的治疗干预措施。这 KU ADRC 将在下一个周期利用其知识和基础设施资产来推动大学的 AD 研究 既得利益并投资于我们的成功，从而使该领域更接近治愈方法。 我们的中心在实验室和临床之间无缝移动，无论是在我们的研究项目方面 支持，以及支持研究者项目所需的基础设施。生活方式干预研究 产生我们呼吁湿实验室研究人员解决的基本机械问题，以及 临床实施和实践现在是干燥实验室、临床和医疗保健服务的重点 调查人员。针对 AD 线粒体成分的研究证明了线粒体基因的作用 在 AD 风险中，线粒体在细胞蛋白质稳态和蛋白质聚集中发挥着关键作用，具体链接 线粒体和 AD 标志蛋白之间的关系，以及如何通过控制大脑能量代谢 生活方式和药理学方法。迄今为止，这些努力使我们创造出新的化合物，这些化合物构成 独特的治疗管道和支持代谢实际研究的临床试验基础设施 对实际 AD 患者的干预。 在 2021-26 年周期中，我们将利用我们的知识和基础设施资产来解决 AD 领域，包括基础知识和护理实施方面的差距。在此周期内，KU ADRC 将致力于 (1) 赋能创新型 AD 和脑衰老研究、教育和临床项目； (2) 驱动器 定义领域的代谢研究，以及（3）为人们带来实用且新颖的代谢导向疗法 床边和诊所。